Longevity Science — March 22, 2026

Key Developments

Study Confirms Biological Aging Accelerates in Distinct Phases, Not Gradually

• What happened: A study highlighted by ScienceAlert this week (published 3 days ago) confirms that the human body does not age at a constant rate — biological aging is characterized by discrete turning points where the rate of aging dramatically accelerates, rather than accumulating damage linearly over time.
• Why it matters: This has profound implications for intervention timing. If aging "jumps" at specific life stages, preventive longevity treatments will need to be timed to pre-empt those accelerations rather than administered uniformly across the lifespan. It also validates a growing class of multi-omic longitudinal studies tracking when biological age diverges sharply from chronological age.
• Stage: Discovery

1 sources

sciencealert.com

Study Reveals a Turning Point When Your Body

Longevity.Technology Pivots to Become an AI Intelligence Company

• What happened: Longevity.Technology revealed this week (4 days ago) that it has been quietly repositioning itself as an AI company focused on longevity intelligence and dealmaking, rather than a purely editorial publication. The platform is now deploying AI systems to analyze the longevity space and facilitate sector investment.
• Why it matters: This signals a broader trend of longevity information infrastructure being rebuilt around machine intelligence. As clinical and investment data in aging science proliferates, AI curation and synthesis tools are becoming the new substrate for research translation and capital allocation in the sector.
• Stage: Commercial

Rapamycin Review: Limited Evidence for Healthy Adults, But Cardiovascular Signal Persists

• What happened: A new review published in Aging (September 2025, recently indexed and circulating widely this week) found no clear clinical evidence that low-dose rapamycin extends healthspan or delays aging in healthy humans, despite robust animal data. However, separate 2025 trial data cited by GetHealthspan showed that short-term mTOR inhibition via rapamycin improved cardiovascular performance and vascular function markers in older adults.
• Why it matters: The divergence between animal data and human trials remains the central challenge for rapamycin advocates. The cardiovascular signal is the strongest human-facing evidence yet and is driving calls for larger controlled trials. This nuanced picture — promising mechanism, limited proven benefit in healthy populations — is increasingly characterizing the whole field.
• Stage: Clinical Trial / Discovery

Stanford Geneticist Anne Brunet Outlines Longevity Research Frontiers

• What happened: A Stanford Report profile (published approximately 1 week ago) featuring genetics professor Anne Brunet breaks down the current state of aging science — including what "aging" means biologically, how lifestyle modulates it, and where the most promising research frontiers lie.
• Why it matters: Brunet's lab works at the intersection of epigenetics, stem cell biology, and aging, making her a key voice in translating hallmarks-of-aging research into mechanistic understanding. The public-facing piece signals a broader effort to mainstream the scientific framing of aging as a tractable biological problem.
• Stage: Discovery

Clinical Trial Watch

PEARL Trial (Rapamycin) — NCT04488601 — Participatory Evaluation of Aging With Rapamycin The PEARL study (a participatory, community-driven rapamycin trial in healthy older adults) continues to be a reference point in current rapamycin discussions. The trial tests whether intermittent low-dose rapamycin (mTOR inhibitor) improves healthspan biomarkers in adults aged 50+. Recent review papers circulating this week cite PEARL as one of the few ongoing human trials with healthy older adults. Status: Active, enrolling.

MILES Trial (Metformin) — NCT02432287 — Metformin in Longevity Study The MILES trial, which tests metformin's impact on gene expression signatures of aging in older adults, continues to be cited in this week's literature on AMPK/mTOR pathway interventions. The trial has contributed data on whether metformin mimics caloric restriction at the transcriptomic level. Status: Completed; results informing ongoing research.

GLP-1 Agonists (Semaglutide/Tirzepatide) — Multiple Active Trials Multiple analyses highlighted this week by GetHealthspan confirm that GLP-1 receptor agonists (drugs like Wegovy/semaglutide) reduce all-cause mortality across several large real-world datasets. This positions GLP-1s as the most commercially advanced and clinically validated longevity-relevant intervention currently available. Multiple Phase III trials for cardiometabolic-adjacent aging indications are active.

Funding & Industry Moves

Los Angeles Emerges as a Longevity Investment Hub

The Los Angeles Times published a major feature today (March 22, 2026) profiling how the LA longevity industry is transforming aging into an investable frontier. The piece covers biotech startups, AI diagnostics companies, and the growing presence of venture capital in the region's healthspan ecosystem. LA is positioned as the second major US hub (after the San Francisco Bay Area) for longevity-focused capital deployment, with its entertainment-healthcare crossover culture driving consumer-facing longevity brands alongside more traditional clinical biotechs.

Biotech Stocks and Longevity Investing: GLP-1s Lead a Maturing Market

Newsweek published an investment trends analysis 2 days ago noting that longevity investing is shifting away from pure "moonshot" science bets toward revenue-generating companies. Novo Nordisk (NVO), the maker of Wegovy (semaglutide), is cited as the prototype: a longevity-relevant company already generating massive commercial returns. The article notes that biotech stocks entered 2026 after a strong 2025 driven by FDA approvals and M&A activity, with longevity now commanding a distinct sub-sector allocation from institutional investors. Separately, New Market Pitch's monthly ranking of top longevity startups by fundraising (updated 2 weeks ago) tracks continued capital flow into the space.

Mechanism & Biomarker Insights

Anti-Aging Peptides Under Renewed Research Scrutiny in 2026

A comprehensive guide published 3 days ago by Spartan Peptides surveys the top peptides being studied for longevity and cellular health in 2026. The compounds reviewed include GHK-Cu (copper peptide with wound healing and anti-senescent properties), Epithalon (pineal-derived, claimed telomerase-activating), MOTS-c (mitochondria-derived peptide that activates AMPK and mimics aspects of exercise adaptation), BPC-157 (systemic healing), TB-500 (thymosin beta-4, tissue repair), and Thymosin Alpha-1 (immune modulation). The review frames these as research-stage compounds with mechanistic plausibility — most have preclinical data but lack robust human trials.

• Mechanism highlight: MOTS-c is particularly notable because it is encoded within mitochondrial DNA (not nuclear DNA), activates AMPK, and responds to metabolic stress — positioning it as a genuine exercise-mimetic candidate that bridges mitochondrial dysfunction (a core hallmark of aging) and cellular energy sensing.
• Therapeutic implication: If MOTS-c's AMPK activation can be replicated pharmacologically at scale, it could provide a route to preserving metabolic resilience in aging muscle tissue without requiring physical exercise capacity the patient may no longer have.

Rapamycin Review in Frontiers Maps Mechanistic Evidence and Gaps

A new review published in PMC (Rapamycin for longevity: the pros, the cons, and future perspectives, indexed June 2025 but widely circulated this week) systematically maps what is known about rapamycin's geroprotective mechanisms versus what remains unproven in humans. Key findings: mTORC1 inhibition is well-validated as extending lifespan in multiple model organisms; the immunosuppressive risk at high doses is the primary clinical barrier; and the intermittent dosing regimens being tested in PEARL and related trials represent the field's best current hypothesis for achieving benefit without immunosuppression. The review also flags that GLP-1 drugs' mortality reduction data — now appearing across multiple large human cohorts — is creating a new comparison benchmark for any would-be longevity drug to meet.

• Mechanism: Rapamycin inhibits mTORC1, reducing cellular protein synthesis and activating autophagy — two processes that decline with age and are linked to cellular senescence accumulation.
• Therapeutic implication: mTOR remains the most pharmacologically validated longevity target, but the human benefit window (dose, schedule, population) is still undefined.

What to Watch Next

1. PEARL Trial interim readout (rapamycin) — The Participatory Evaluation of Aging With Rapamycin trial (NCT04488601) is expected to release additional biomarker data from its healthy older adult cohort in Q2 2026. This will be the most important near-term human data point for the rapamycin-as-geroprotective hypothesis.

2. Longevity.Technology AI Platform Launch Details — Following this week's announcement that Longevity.Technology has repositioned as an AI company, the sector is watching for specifics on their intelligence and dealmaking product. A formal reveal is expected within days-to-weeks, and could reshape how institutional investors access longevity sector research.

3. LA Longevity Ecosystem Conference Season (Spring 2026) — The Los Angeles Times feature published today signals that a cluster of longevity-focused investment events and conference presentations is building in the LA metro area through Q2 2026. Watch for announcements from Calico, Human Longevity Inc., and new VC-backed entrants based in Southern California to surface at these events.